Tag - PRTC

Developments

PureTech’s Seaport reports positive data from trial of GlyphAgo in GAD

PureTech Health (NASDAQ: PRTC; LSE: PRTC) has announced that its founded entity, closely held Seaport Therapeutics, has reported positive proof of concept topline data from portions of its ongoing Phase 1 proof-of...

April 2, 2026

Executive Moves

PureTech appoints Robert Lyne as CEO

PureTech Health (NASDAQ: PRTC; LSE: PRTC) has announced the appointment of Robert Lyne as chief executive officer (CEO), and member of the board of directors, effective immediately. Mr. Lyne has served as interim CEO...

December 18, 2025

Feature

PureTech targeting dysfunctions in brain, gut, immune system

By Len Zehr With eight clinical-stage studies underway, including two pivotal trials expected to readout later this year, PureTech Health (LSE:PRTC) is taking a novel approach to drug development, targeting serious...

July 18, 2017

Tag - PRTC

PureTech’s Seaport reports positive data from trial of GlyphAgo in GAD

PureTech appoints Robert Lyne as CEO

PureTech targeting dysfunctions in brain, gut, immune system

Subscribe